Theresa Heah

Theresa Heah, an accomplished leader in the biotech industry, has more than 2 decades of global experience in spearheading the development and commercialization of innovative therapies. She most recently served as Chief Executive Officer, President, and Board Member at Intergalactic Therapeutics.

Theresa’s career spans the core business areas of small molecules and biologics to gene therapy development and commercialization in early-stage private-staged companies (Fovea Pharmaceuticals [acquired by Sanofi], AsclepiX Therapeutics, and Kriya Therapeutics), public-staged companies (Aerie Pharmaceuticals [acquired by Alcon], Allergan [acquired by AbbVie], and AGTC [acquired by Syncona, rebranded as Beacon Therapeutics]), and big pharmaceutical companies (Bayer Healthcare and Sanofi).

With a diverse background spanning small molecules, biologics, and gene therapies, Theresa has navigated successful M&A deals, venture capital fundraising, and the launch of groundbreaking products in various therapeutic areas. Her achievements include multiple regulatory approvals in the US, Europe, and Japan for revolutionary therapies such as Ozurdex, Eylea, Rhopressa, and Rocklatan.

Theresa holds a medical degree from Guy’s, King’s and St. Thomas’ School of Medicine, King’s College, University of London, and an Executive MBA from the European School of Management & Technology (ESMT), Berlin.